Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Authors

Santiago Ponce

Published

December 5, 2020

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(20)30539-8

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Authors

Santiago Ponce

Published

December 5, 2020

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(20)30539-8

Paper

Paper

Paper

Paper

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Supporters

Journal

Topics

DOI

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Supporters

Journal

Topics

DOI